CPRX
Catalyst Pharmaceuticals, Inc.
Biotechnology
Market Cap$3.74B
5Y Perf.+608.1%
Compare Stocks
3 / 10Try these comparisons:
Stock Comparison
CPRX vs RARE vs FOLD
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.55B
5Y Perf.-62.1%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.47B
5Y Perf.+15.9%
CPRX vs RARE vs FOLD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CPRX | RARE | FOLD |
|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $3.74B | $2.55B | $4.47B |
| Revenue (TTM) | $589M | $669M | $599M |
| Net Income (TTM) | $214M | $-609M | $-14M |
| Gross Margin | 85.2% | 83.6% | 89.5% |
| Operating Margin | 43.8% | -83.9% | 5.5% |
| Forward P/E | 16.2x | — | 40.6x |
| Total Debt | $2M | $1.28B | $444M |
| Cash & Equiv. | $709M | $434M | $214M |
CPRX vs RARE vs FOLD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CPRX
RARE
FOLD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Catalyst Pharmaceut… (CPRX) | 100 | 708.1 | +608.1% |
| Ultragenyx Pharmace… (RARE) | 100 | 37.9 | -62.1% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CPRX vs RARE vs FOLD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CPRX and FOLD are tied at the top with 3 categories each — the right choice depends on your priorities. Amicus Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CPRX
Catalyst Pharmaceuticals, Inc.
The Long-Run Compounder
CPRX has the current edge in this matchup, primarily because of its strength in long-term compounding and sleep-well-at-night.
- 49.2% 10Y total return vs FOLD's 125.0%
- Lower volatility, beta 0.88, Low D/E 0.2%, current ratio 6.08x
- Lower P/E (16.2x vs 40.6x)
Best for: long-term compounding and sleep-well-at-night
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.63
- Rev growth 32.3%, EPS growth 64.7%, 3Y rev CAGR 20.0%
- Beta 0.63, current ratio 3.39x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FOLD | 32.3% revenue growth vs CPRX's 19.8% |
| Value | CPRX | Lower P/E (16.2x vs 40.6x) |
| Quality / Margins | CPRX | 36.4% margin vs RARE's -91.0% |
| Stability / Safety | FOLD | Beta 0.63 vs RARE's 1.42 |
| Dividends | Tie | None of these 3 stocks pay a meaningful dividend |
| Momentum (1Y) | FOLD | +134.1% vs RARE's -26.0% |
| Efficiency (ROA) | CPRX | 19.4% ROA vs RARE's -45.8%, ROIC 83.9% vs -89.4% |
CPRX vs RARE vs FOLD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
Segment breakdown not available.
CPRX vs RARE vs FOLD — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCPRXLAGGINGRARE
Who Leads Where
CPRX leads in 3 of 6 categories
FOLD leads 1 • RARE leads 0 • 1 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
FOLDAmicus Therapeutics, …
1leads
CPRXCatalyst Pharmaceutic…
3leads
6 Total Categories
CATEGORYLEADERvs FOLDvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
CPRX3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CPRX7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CPRX5/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — CPRX and FOLD each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE and CPRX operate at a comparable scale, with $669M and $589M in trailing revenue. CPRX is the more profitable business, keeping 36.4% of every revenue dollar as net income compared to RARE's -91.0%. On growth, FOLD holds the edge at +19.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|
| RevenueTrailing 12 months | $589M | $669M | $599M |
| EBITDAEarnings before interest/tax | $295M | -$536M | $40M |
| Net IncomeAfter-tax profit | $214M | -$609M | -$14M |
| Free Cash FlowCash after capex | $209M | -$487M | $10M |
| Gross MarginGross profit ÷ Revenue | +85.2% | +83.6% | +89.5% |
| Operating MarginEBIT ÷ Revenue | +43.8% | -83.9% | +5.5% |
| Net MarginNet income ÷ Revenue | +36.4% | -91.0% | -2.3% |
| FCF MarginFCF ÷ Revenue | +35.4% | -72.8% | +1.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.6% | -2.4% | +19.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -9.1% | -17.2% | +3.8% |
Evenly matched — CPRX and FOLD each lead in 3 of 6 comparable metrics.
Valuation Metrics
CPRX leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, CPRX's 10.3x EV/EBITDA is more attractive than FOLD's 140.6x.
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|
| Market CapShares × price | $3.7B | $2.5B | $4.5B |
| Enterprise ValueMkt cap + debt − cash | $3.0B | $3.4B | $4.7B |
| Trailing P/EPrice ÷ TTM EPS | 18.17x | -4.45x | -80.50x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.23x | — | 40.62x |
| PEG RatioP/E ÷ EPS growth rate | 0.97x | — | — |
| EV / EBITDAEnterprise value multiple | 10.27x | — | 140.62x |
| Price / SalesMarket cap ÷ Revenue | 6.35x | 3.79x | 8.46x |
| Price / BookPrice ÷ Book value/share | 4.07x | — | 22.73x |
| Price / FCFMarket cap ÷ FCF | 17.92x | — | — |
CPRX leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
CPRX leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
CPRX delivers a 22.5% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-6 for RARE. CPRX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 2.29x. On the Piotroski fundamental quality scale (0–9), FOLD scores 5/9 vs RARE's 4/9, reflecting solid financial health.
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|
| ROE (TTM)Return on equity | +22.5% | -6.1% | -6.1% |
| ROA (TTM)Return on assets | +19.4% | -45.8% | -1.6% |
| ROICReturn on invested capital | +83.9% | -89.4% | +4.8% |
| ROCEReturn on capital employed | +30.6% | -46.4% | +4.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.00x | — | 2.29x |
| Net DebtTotal debt minus cash | -$707M | $842M | $230M |
| Cash & Equiv.Liquid assets | $709M | $434M | $214M |
| Total DebtShort + long-term debt | $2M | $1.3B | $444M |
| Interest CoverageEBIT ÷ Interest expense | — | -14.49x | 1.11x |
CPRX leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CPRX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CPRX five years ago would be worth $65,353 today (with dividends reinvested), compared to $2,241 for RARE. Over the past 12 months, FOLD leads with a +134.1% total return vs RARE's -26.0%. The 3-year compound annual growth rate (CAGR) favors CPRX at 20.7% vs RARE's -18.0% — a key indicator of consistent wealth creation.
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|
| YTD ReturnYear-to-date | +31.8% | +9.9% | +1.5% |
| 1-Year ReturnPast 12 months | +32.4% | -26.0% | +134.1% |
| 3-Year ReturnCumulative with dividends | +75.7% | -44.9% | +19.0% |
| 5-Year ReturnCumulative with dividends | +553.5% | -77.6% | +50.9% |
| 10-Year ReturnCumulative with dividends | +4915.6% | -58.9% | +125.0% |
| CAGR (3Y)Annualised 3-year return | +20.7% | -18.0% | +6.0% |
CPRX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs RARE's 61.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.88x | 1.42x | 0.63x |
| 52-Week HighHighest price in past year | $32.56 | $42.37 | $14.50 |
| 52-Week LowLowest price in past year | $19.05 | $18.29 | $5.51 |
| % of 52W HighCurrent price vs 52-week peak | +93.7% | +61.2% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 74.2 | 61.0 | 72.2 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 1.8M | 3.0M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CPRX as "Buy", RARE as "Buy", FOLD as "Buy". Consensus price targets imply 98.6% upside for RARE (target: $52) vs 0.1% for FOLD (target: $15).
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $33.00 | $51.50 | $14.50 |
| # AnalystsCovering analysts | 16 | 33 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CPRX leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). FOLD leads in 1 (Risk & Volatility). 1 tied.
Best OverallCatalyst Pharmaceuticals, I… (CPRX)Leads 3 of 6 categories
Loading custom metrics...
CPRX vs RARE vs FOLD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CPRX or RARE or FOLD a better buy right now?
For growth investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger pick with 32. 3% revenue growth year-over-year, versus 19. 8% for Catalyst Pharmaceuticals, Inc. (CPRX). Catalyst Pharmaceuticals, Inc. (CPRX) offers the better valuation at 18. 2x trailing P/E (16. 2x forward), making it the more compelling value choice. Analysts rate Catalyst Pharmaceuticals, Inc. (CPRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CPRX or RARE or FOLD?
On forward P/E, Catalyst Pharmaceuticals, Inc.
is actually cheaper at 16. 2x.
03Which is the better long-term investment — CPRX or RARE or FOLD?
Over the past 5 years, Catalyst Pharmaceuticals, Inc.
(CPRX) delivered a total return of +553. 5%, compared to -77. 6% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: CPRX returned +49. 2% versus RARE's -58. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CPRX or RARE or FOLD?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 63β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 125% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Catalyst Pharmaceuticals, Inc. (CPRX) carries a lower debt/equity ratio of 0% versus 2% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CPRX or RARE or FOLD?
By revenue growth (latest reported year), Amicus Therapeutics, Inc.
(FOLD) is pulling ahead at 32. 3% versus 19. 8% for Catalyst Pharmaceuticals, Inc. (CPRX). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 64. 7% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, CPRX leads at 40. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CPRX or RARE or FOLD?
Catalyst Pharmaceuticals, Inc.
(CPRX) is the more profitable company, earning 36. 4% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CPRX leads at 43. 8% versus -79. 5% for RARE. At the gross margin level — before operating expenses — FOLD leads at 90. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CPRX or RARE or FOLD more undervalued right now?
On forward earnings alone, Catalyst Pharmaceuticals, Inc.
(CPRX) trades at 16. 2x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 24. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 98. 6% to $51. 50.
08Which pays a better dividend — CPRX or RARE or FOLD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is CPRX or RARE or FOLD better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +125. 0% 10Y return). Both have compounded well over 10 years (FOLD: +125. 0%, RARE: -58. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CPRX and RARE and FOLD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(CPRX: 7.6% · RARE: -2.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.